EXTL3抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P08299(EXTL3 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P08299(EXTL3 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The EXTL3 antibody targets the EXTL3 protein, a member of the EXT-like (EXTL) gene family, which includes tumor suppressors involved in heparan sulfate proteoglycan (HSPG) biosynthesis. EXTL3. also known as EXTR1 or KIAA0510. encodes a glycosyltransferase critical for chain elongation during HSPG synthesis. HSPGs are essential components of the extracellular matrix and cell surfaces, regulating cell signaling, adhesion, and proliferation. EXTL3 catalyzes the addition of glucuronic acid and N-acetylglucosamine residues to the growing heparan sulfate chain, a process vital for maintaining tissue homeostasis and developmental signaling pathways like Wnt, Hedgehog, and FGF.

Structurally, EXTL3 contains an N-terminal transmembrane domain and a C-terminal glycosyltransferase module. Mutations or dysregulation of EXTL3 are linked to hereditary multiple exostoses (HME), a skeletal disorder characterized by benign bone tumors, and have been implicated in cancers such as leukemia and hepatocellular carcinoma. Antibodies against EXTL3 are widely used in research to study its expression, localization, and functional roles in normal physiology and disease. They enable techniques like Western blotting, immunohistochemistry, and co-immunoprecipitation, aiding in the exploration of EXTL3’s interaction networks and mechanistic contributions to pathologies. Such antibodies are crucial tools for validating EXTL3 as a potential therapeutic target or biomarker in oncology and genetic disorders.